close
References
  1. Centers for Disease Control and Prevention, United States Public Health System. Preexposure prophylaxis for the prevention of HIV infection in the United States – 2017 update: a clinical practice guideline. www.cdc.gov/hiv/pdf/risk/prep/cdc-hiv-prep-guidelines-2017.pdf. March 2018. Accessed August 16, 2020.
  2. Centers for Disease Control and Prevention. HIV in the United States by region. www.cdc.gov/hiv/statistics/overview/geographicdistribution.html. Updated July 2, 2020. Accessed August 16, 2020.
  3. Centers for Disease Control and Prevention. HIV basic statistics. www.cdc.gov/hiv/basics/statistics.html. Updated July 1, 2020. Accessed August 16, 2020.
  4. Centers for Disease Control and Prevention. HIV and women. www.cdc.gov/hiv/group/gender/women/index.html. Updated May 18, 2020. Accessed August 16, 2020.
  5. Truvada prescribing information. Gilead Sciences, Inc.; 2020.
  6. Descovy prescribing information. Gilead Sciences, Inc.; 2020.
  7. Centers for Disease Control and Prevention. PrEP. www.cdc.gov/hiv/basics/prep.html. Updated June 4, 2020. Accessed August 16, 2020.
  8. Smith DK, Van Handel M, Grey J. Estimates of adults with indications for HIV pre-exposure prophylaxis by jurisdiction, transmission risk group, and race/ethnicity, United States, 2015. Ann Epidemiol. 2018;28(12):850-857.
  9. Smith DK, Van Handel M, Grey JA. By race/ethnicity, blacks have highest number needing PrEP in the United States, 2015. Presented at the Conference on Retroviruses and Opportunistic Infections; Boston, MA; March 4-7, 2018. Abstract 86.
  10. Finlayson T, Cha S, Xia M, et al. Changes in HIV preexposure prophylaxis awareness and use among men who have sex with men — 20 urban areas, 2014 and 2017. MMWR Morb Mortal Wkly Rep. 2019;68(27):597-603.
  11. Siegler AJ, Bratcher A, Weiss KM, Mouhanna F, Ahlschlager L, Sullivan PS. Location location location: an exploration of disparities in access to publicly listed PrEP clinics in the United States. Ann Epidemiol. 2018;28(12):858-64.
  12. Siegler AJ, Mouhanna F, Giler RM, et al. The prevalence of PrEP use and the PrEP-to-need ratio in the fourth quarter of 2017, United States. Ann Epidemiol. 2018;28(12):841-849.
  13. Conniff J, Evensen A. Preexposure prophylaxis (PrEP) for HIV prevention: the primary care perspective. J Am Board Fam Med. 2016;29(1):143-151.
  14. Flash C, Landovitz R, Giler RM, et al. Two years of Truvada for pre-exposure prophylaxis utilization in the US. J Int AIDS Soc. 2014;17(4 Suppl 3):19730.
  15. Pleuhs B, Quinn KG, Walsh JL, Petroll AE, John SA. Health care provider barriers to HIV pre-exposure prophylaxis in the United States: a systematic review. AIDS Patient Care STDS. 2020;34(3):111-123.
  16. Patel AS, Goparaju L, Sales JM, et al. Brief report: PrEP eligibility among at-risk women in the Southern United States: associated factors, awareness, and acceptability. J Acquir Immune Defic Syndr. 2019;80(5):527-532.
  17. Workowski KA, Bolan GA, Centers for Disease Control and Prevention. Clinical prevention guidance. Sexually transmitted diseases treatment guidelines, 2015. MMWR Recomm Rep. 2015;64(RR-03):1-137.
  18. National Institutes of Health. Clear communication: cultural respect. www.nih.gov/institutes-nih/nih-office-director/office-communications-public-liaison/clear-communication/cultural-respect. Updated February 15, 2017. Accessed August 16, 2020.
  19. Bagchi AD. A structural competency curriculum for primary care providers to address the opioid use disorder, HIV, and hepatitis C syndemic. Front Public Health. 2020;8:210. 
  20. Agner J. Moving from cultural competence to cultural humility in occupational therapy: a paradigm shift. Am J Occup Ther. 2020;74(4):7404347010p1-7404347010p7.
  21. Golub S, New York University Department of Health and Mental Hygiene. New York State Department of Health Aids Institute Clinical Guidelines Program. GOALS framework for sexual history taking in primary care. www.hivguidelines.org/sti-care/selected-resources/#tab_3. July 2019. Accessed August 16, 2020.
  22. Tanner MR, Miele P, Carter W, et al. Preexposure prophylaxis for prevention of HIV acquisition among adolescents: clinical considerations, 2020. MMWR Recomm Rep. 2020;69(No. RR-3):1-12.
  23. Grant RM, Lama JR, Anderson PL, et al. Preexposure chemoprophylaxis for HIV prevention in men who have sex with men. N Engl J Med. 2010;363(27):2587-2599.
  24. Baeten JM, Donnell D, Ndase P, et al. Antiretroviral prophylaxis for HIV prevention in heterosexual men and women. N Engl J Med. 2012;367(5):399-410.
  25. Thigpen MC, Kebaabetswe PM, Paxton LA, et al. N Engl J Med. 2012;367(5):423-434.
  26. Centers for Disease Control and Prevention, United States Public Health System. Preexposure prophylaxis for the prevention of HIV infection in the United States – 2017 update: clinical providers’ supplement. www.cdc.gov/hiv/pdf/risk/prep/cdc-hiv-prep-provider-supplement-2017.pdf. March 2018. Accessed August 16, 2020.
  27. San Francisco Department of Public Health. Roles and responsibilities in providing PrEP: an outline. https://getsfcba.org/resources/roles-and-responsibilities-in-providing-prep-an-outline. 2015. Accessed August 16, 2020.
  28. Calabrese SK, Krakower DS, Mayer KH. Integrating HIV preexposure prophylaxis (PrEP) into routine preventive health care to avoid exacerbating disparities. Am J Public Health. 2017;107(12):1883-1889.
  29. Kasonde M, Niska RW, Rose C, et al. Bone mineral density changes among HIV-uninfected young adults in a randomized trial of pre-exposure prophylaxis with tenofovir emtricitabine or placebo in Botswana. PloS One. 2014;9(3):e90111.
  30. Grant R, Mulligan K, McMahan V, et al. Recovery of bone mineral density after stopping oral HIV pre-exposure prophylaxis. Presented at the Conference on Retroviruses and Opportunistic Infections; Boston, MA; February 22-25, 2016. Abstract 48LB.
  31. Centers for Disease Control and Prevention. PEP. www.cdc.gov/hiv/basics/pep.html. Updated August 6, 2019. Accessed August 16, 2020.
  32. Centers for Disease Control and Prevention, United States Public Health Service. Updated guidelines for the antiretroviral postexposure prophylaxis after sexual, injection drug use, or nonoccupational exposure to HIV—United States, 2016. https://stacks.cdc.gov/view/cdc/38856. April 18, 2016. Accessed August 16, 2020.
  33. Centers for Disease Control and Prevention. Post-exposure prophylaxis (PEP). www.cdc.gov/hiv/clinicians/prevention/pep.html#:~:text
    =The%20current%20preferred%20regimen%20is,risks%20posed%20by%20the%20
    medication
    . Updated May 13, 2020. Accessed August 16, 2020.